RayKnowChina Research Map
Shortlist

HangzhouZhejiang University School of Medicine

Second Affiliated Hospital, Zhejiang University

浙江大学医学院附属第二医院

Listed for 33 of the 53 diseases this site covers, from the research papers it led and the trials registered with it as lead sponsor or site.

Research activity in public records, not a rating of care. Whether the hospital can help a particular patient is for the hospital and the treating doctor to say.

Official links opened and checked on 2026-11-08.

Getting in touch

Research at Second Affiliated Hospital, Zhejiang University

Choose a disease to see the papers and trials behind it. Each tile shows papers led, 2021–2025, and papers per year.

Only the 53 diseases this site covers. A disease it is not listed for means this hospital did not meet the listing rule for that disease in these records; it does not mean the hospital does not treat it. Which hospitals are listed

  1. Nasopharyngeal carcinoma鼻咽癌1 paper led
  2. Oesophageal squamous cell carcinoma食管鳞状细胞癌4 papers led3 open trials led
  3. Hepatocellular carcinoma肝细胞癌68 papers led9 open trials led
  4. Stomach cancer胃癌58 papers led6 open trials led
  5. Retinoblastoma视网膜母细胞瘤1 paper led
  6. Chordoma脊索瘤0 papers led
  7. Osteosarcoma骨肉瘤16 papers led
  8. Gastrointestinal stromal tumour胃肠道间质瘤4 papers led
  9. Neuroblastoma神经母细胞瘤3 papers led
  10. Ewing sarcoma尤文肉瘤0 papers led
  11. Multiple myeloma多发性骨髓瘤5 papers led2 open trials led
  12. Haemophagocytic lymphohistiocytosis噬血细胞性淋巴组织细胞增生症2 papers led
  13. Thrombotic thrombocytopenic purpura血栓性血小板减少性紫癜1 paper led
  14. Neuromyelitis optica spectrum disorder视神经脊髓炎谱系疾病7 papers led
  15. Myasthenia gravis重症肌无力4 papers led
  16. Moyamoya disease烟雾病12 papers led
  17. Wilson disease肝豆状核变性(Wilson 病)8 papers led2 open trials led
  18. Anti-NMDA receptor encephalitis抗 NMDA 受体脑炎4 papers led
  19. Takayasu arteritis大动脉炎0 papers led
  20. Idiopathic pulmonary fibrosis特发性肺纤维化4 papers led
  21. Amyotrophic lateral sclerosis肌萎缩侧索硬化症6 papers led
  22. Fabry disease法布雷病0 papers led
  23. Pompe disease庞贝病0 papers led
  24. Duchenne muscular dystrophy杜氏肌营养不良1 paper led
  25. Behçet disease白塞病0 papers led
  26. Alport syndromeAlport 综合征1 paper led
  27. IgA nephropathyIgA 肾病2 papers led
  28. Osteogenesis imperfecta成骨不全症0 papers led
  29. Congenital diaphragmatic hernia先天性膈疝1 paper led
  30. Hirschsprung disease先天性巨结肠1 paper led
  31. Hereditary angioedema遗传性血管性水肿1 paper led
  32. Familial adenomatous polyposis家族性腺瘤性息肉病4 papers led
  33. Leber hereditary optic neuropathyLeber 遗传性视神经病变0 papers led

Not listed for: Hepatoblastoma, B-cell acute lymphoblastic leukaemia, Aplastic anaemia, Beta thalassaemia, Haemophilia A, Atypical haemolytic uraemic syndrome, Fanconi anaemia, IgG4-related disease, Biliary atresia, Hepatic echinococcosis, Lymphangioleiomyomatosis, Spinal muscular atrophy, Gaucher disease, Niemann–Pick disease type C, Primary biliary cholangitis, Primary sclerosing cholangitis, Inherited epidermolysis bullosa, Majeed syndrome, NGLY1 deficiency, ISG15 deficiency.

Cancer

Nasopharyngeal carcinoma

鼻咽癌

Led 1 of the 2,375 English-language PubMed papers on nasopharyngeal carcinoma with an author in mainland China, 2021–2025: 0.04%.

Papers led
1
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

8 hospitals in Hangzhou for nasopharyngeal carcinoma176 hospitals in China for nasopharyngeal carcinoma

No open trial on nasopharyngeal carcinoma lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Cancer

Oesophageal squamous cell carcinoma

食管鳞状细胞癌

Led 4 of the 2,923 English-language PubMed papers on oesophageal squamous cell carcinoma with an author in mainland China, 2021–2025: 0.1%.

Papers led
4
2021–2025
Trials led
6
any status, ClinicalTrials.gov
Open trials led
3
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 1120242025: 222025

6 hospitals in Hangzhou for oesophageal squamous cell carcinoma191 hospitals in China for oesophageal squamous cell carcinoma

Open trials with this hospital 3

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Neoadjuvant Ivonescimab(AK112) Combined With Chemotherapy in Patients With Resectable Esophageal Squamous Cell Carcinoma
    Phase
    Phase 2
    Started
    2026-06
    Registry
    NCT07244978

    Age 18 years to 75 years (registered criteria)

    Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou

  2. Recruiting
    Camrelizumab, Chemotherapy and Ivarmacitinib in Patients With Resectable Esophageal Squamous Cell Carcinoma
    Phase
    Phase 2
    Started
    2026-08
    Registry
    NCT07505186

    Age 18 years to 75 years (registered criteria)

    Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou

  3. Recruiting
    Adbelimumab Combined With Chemotherapy and Apatinib in Patients With Resectable Esophageal Squamous Cell Carcinoma
    Phase
    Phase 2
    Started
    2024-08
    Registry
    NCT06576973

    Age 18 years to 75 years (registered criteria)

    Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesNeoadjuvant & combined treatmentImmunotherapyImaging & AI
Papers it led4
  1. Discovery of LD-110 as an Effective LSD1 PROTAC Degrader for the Treatment of Esophagus Squamous Cancer.2025Journal of medicinal chemistryFree full text
  2. Neoadjuvant serplulimab combined with chemotherapy for resectable oesophageal squamous cell carcinoma: a single-arm, phase 2 trial.2025Nature communicationsFree full text
  3. Camrelizumab-induced oral lichenoid reaction with subepithelial CD4+ T-cell infiltration.2024Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners
  4. Long Non-Coding RNA OIP5-AS1 Inhibits the Proliferation and Migration of Esophageal Squamous Carcinoma Cells by Targeting FOXD1/miR-30a-5p Axis and the Effect of Micro- and Nano-Particles on Targeting Transfection System.2021Journal of biomedical nanotechnology
All its trials on ClinicalTrials.gov, any status9
  1. Camrelizumab, Chemotherapy and Ivarmacitinib in Patients With Resectable Esophageal Squamous Cell CarcinomaRecruitingNCT07505186Lead sponsorPhase 2Start 2026-08
  2. Neoadjuvant Ivonescimab(AK112) Combined With Chemotherapy in Patients With Resectable Esophageal Squamous Cell CarcinomaRecruitingNCT07244978Lead sponsorPhase 2Start 2026-06
  3. Adbelimumab Combined With Chemotherapy and Apatinib in Patients With Resectable Esophageal Squamous Cell CarcinomaRecruitingNCT06576973Lead sponsorPhase 2Start 2024-08
  4. Cadonilimab/Anlotinib in Locally Advanced or Relapsed/Metastatic ESCC Patients After Failure of PD-1 Combined With Platinum-containing ChemotherapyStatus unknownNCT05990231Lead sponsorPhase 2Start 2023-09
  5. Serplulimab Combined With Chemotherapy in Patients With Resectable Esophageal Squamous Cell CarcinomaActive, not recruitingNCT05659251Lead sponsorPhase 2Start 2022-12
  6. Carrelizumab, Chemotherapy and Apatinib in the Neoadjuvant Treatment of Resectable Esophageal Squamous Cell CarcinomaActive, not recruitingNCT04666090Lead sponsorPhase 2Start 2020-11
  7. A Study of CS1001 in Subjects With Esophageal Squamous Cell CarcinomaCompletedNCT04187352Study sitePhase 3Start 2019-12
  8. Study of Pembrolizumab (MK-3475) Versus Investigator's Choice of Chemotherapy for Participants With Advanced Esophageal/Esophagogastric Junction Carcinoma That Progressed After First-Line Therapy (MK-3475-181/KEYNOTE-181)-China Extension StudyCompletedNCT03933449Study sitePhase 3Start 2016-12
  9. Nimotuzumab in Combined With Paclitaxel and Cisplatin for Treatment of Metastatic Esophageal Squamous Cell CarcinomaStatus unknownNCT02611700Study sitePhase 3Start 2015-11
More papers found outside PubMed (not counted)8
  1. 1319 First-in-human study of a personalized neoantigen peptide vaccine (iNeo-Vac-P01) for postoperative esophageal cancer in a Chinese cohort2025Journal for ImmunoTherapy of Cancerconference-abstract
  2. Abstract 2876: Spatial immune cell atlas predicts the sensitivity to neoadjuvant PD-1 blockade treatment combined with radiotherapy in resectable esophageal squamous cell carcinoma2024Cancer Researchconference-abstract
  3. Clinical long-term oncologic outcomes of endoscopic noncurative resection for superficial esophageal squamous cell carcinoma: A single-center retrospective study2024Research Squarepreprint
  4. Clinical pathological characteristics and expression of 328 proteins and their impact on survival in over 20,000 cases of esophageal squamous cell carcinoma and colorectal adenocarcinoma2024Chinese Science Bulletin (Chinese Version)article
  5. KC1036, a novel oral multi-kinase inhibitor, in patients with previously treated advanced esophageal squamous cell carcinoma (ESCC): Results from a multicenter, single-arm phase II trial.2023Journal of Clinical Oncologyconference-abstract
  6. Abstract 6124: Interleukin-1β and exosomal M6PR secreted by serglycin-overexpressing esophageal cancer cells instigate fibroblasts and endothelial cells to promote esophageal cancer progression2022Cancer Researchconference-abstract
  7. Additional file 1 of OTUB2 Regulates YAP1/TAZ to Promotes the Progression of Esophageal Squamous Cell Carcinoma2022Figsharedataset
  8. Downregulation of long noncoding RNA breast cancer anti-estrogen resistance 4 inhibits cell proliferation, invasion, and migration in esophageal squamous cell carcinoma by regulating the microRNA-181c-5p/LIM and SH3 protein 1 axis2022Figsharedataset

Run the PubMed searchClinicalTrials.gov

Cancer

Hepatocellular carcinoma

肝细胞癌

Led 68 of the 14,765 English-language PubMed papers on hepatocellular carcinoma with an author in mainland China, 2021–2025: 0.5%.

Papers led
68
2021–2025
Trials led
27
any status, ClinicalTrials.gov
Open trials led
9
recruiting or about to
Open trials as a site
4
led by another institution
Papers led per year
2021: 111120212022: 161620222023: 121220232024: 9920242025: 19192025

7 hospitals in Hangzhou for hepatocellular carcinoma192 hospitals in China for hepatocellular carcinoma

Open trials with this hospital 13

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Prospective, Randomized Study of TACE Combined With Sintilimab, Bevacizumab, and Ipilimumab N01 Treating Advanced HCC
    Phase
    Phase 2
    Started
    2026-03
    Registry
    NCT07422753

    Age 18 years to 75 years (registered criteria)

    Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou

  2. Recruiting
    Construction and Clinical Validation of a Predictive Model for Postoperative Adjuvant Therapy in Hepatocellular Carcinoma Based on Whole-Slide Digital Pathological Images and Deep Learning
    Phase
    Not given
    Started
    2025-11
    Registry
    NCT07417800

    Age 18 years to Not stated (registered criteria)

    Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou

  3. Recruiting
    Study on the Classification of Comprehensive Treatment Effect of Hepatocellular Carcinoma
    Phase
    N/A
    Started
    2024-09
    Registry
    NCT06542796

    Age 18 years to 75 years (registered criteria)

    Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou

  4. Recruiting
    Early-stage Detection of Liver Cancer by Proteins in Peripheral Blood
    Phase
    Not given
    Started
    2024-02
    Registry
    NCT06544083

    Age 18 years to 75 years (registered criteria)

    Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou

  5. Recruiting
    Stereotactic Body Radiation Therapy for the Safety and Prognosis of Small Intrahepatic Recurrent HCC
    Phase
    N/A
    Started
    2023-05
    Registry
    NCT05596630

    Age 18 years to 80 years (registered criteria)

    Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou

  6. Recruiting
    Raman Spectroscopy-Based Deep Learning Model for Early Pan-Cancer Early Diagnosis
    Phase
    Not given
    Started
    2022-09
    Registry
    NCT06822413

    Age not stated (registered criteria)

    Led by Second Affiliated Hospital, Zhejiang University; 3 listed hospitals as study sitesHangzhou, Nanchang, Shanghai

  7. Recruiting
    RFA Plus Carrizumab vs Carrizumab Alone for HCC
    Phase
    Phase 2
    Started
    2020-08
    Registry
    NCT04150744

    Age 18 years to 75 years (registered criteria)

    Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou

  8. Not yet recruiting
    Exploration of Sintilimab + Bevacizumab + AG Chemotherapy as First-Line Treatment for Unresectable Advanced/Metastatic Cholangiocarcinoma
    Phase
    Phase 2
    Started
    2026-01
    Registry
    NCT07328802

    Age 18 years to 75 years (registered criteria)

    Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou

  9. Not yet recruiting
    Adjuvant Stereotactic Body Radiotherapy (SBRT) for Hepatocellular Carcinoma After Hepatectomy With Narrow Margin: a Prospective, Multi-center, Randomized Controlled, Open-labelled, Phase III Study
    Phase
    N/A
    Started
    2023-03
    Registry
    NCT05602974

    Age 18 years to 75 years (registered criteria)

    Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou

  10. Recruiting
    ABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 Overexpression
    Phase
    Phase 2
    Started
    2025-06
    Registry
    NCT07327034

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 39 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Ganzhou, Guangzhou, Guilin, Hangzhou, Hefei, Jinan, Nanchang, Nanjing, Nanning, Nantong, Shanghai, Shenyang, Tianjin, Wuhan, Xi'an, Xuzhou, Yinchuan, Zhengzhou

  11. Recruiting
    CT011 Autologous CAR-T Cells in Patients With Hepatocellular Carcinoma at Risk of Recurrence After Surgical Resection
    Phase
    Phase 1
    Started
    2023-10
    Registry
    NCT06560827

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 14 listed hospitals as study sitesBeijing, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Shanghai, Shenyang, Tianjin, Wuhan, Zhengzhou

  12. Not yet recruiting
    Multimodal Thermal Therapy With Targeted and Immunotherapy for Untreated Unresectable HCC
    Phase
    N/A
    Started
    2026-10
    Registry
    NCT07596134

    Age 18 years to 80 years (registered criteria)

    Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesHangzhou, Nanchang, Taizhou

  13. Not yet recruiting
    29-Gene Liver Cancer Subtype and Immunotherapy Effectiveness
    Phase
    Not given
    Started
    2025-08
    Registry
    NCT07100236

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 12 listed hospitals as study sitesBeijing, Fuzhou, Guangzhou, Hangzhou, Hefei, Shanghai, Wenzhou, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesImaging, AI & early detectionRecurrence & prognosisImmunotherapy & targeted drugs
Departments in papersSurgery (general/hepatobiliary/pancreatic)Radiology / nuclear medicineMedical oncologyRadiation oncology

Over half of these papers are lab or animal studies.

Papers it led68
  1. Quantitative analysis of enhanced CT in predicting microvascular invasion and pathological grading of hepatocellular carcinoma.2026European radiology
  2. A pH-Sensitive Nanosized Covalent-Organic Polymer for Enhanced Tumor Photodynamic Immunotherapy by Hypoxia Relief and STAT3 Inhibition.2025Advanced science (Weinheim, Baden-Wurttemberg, Germany)Free full text
  3. Lactate drives senescence-resistant lineages in hepatocellular carcinoma via histone H2B lactylation of NDRG1.2025Cancer letters
  4. Network meta-analysis of the efficacy and safety of ablation for hepatocellular carcinoma under different imaging guidance.2025Clinical radiology
  5. Heterogeneity in polyamine metabolism dictates prognosis and immune checkpoint blockade response in hepatocellular carcinoma.2025Frontiers in immunologyFree full text
  6. SPP1 promotes malignant characteristics and drug resistance in hepatocellular carcinoma by activating fatty acid metabolic pathway.2025Functional & integrative genomics
  7. METTL4 and METTL5 as biomarkers for recurrence-free survival in hepatocellular carcinoma patients.2025Future oncology (London, England)Free full text
  8. Protective Effects of GalNac-Modified Red Blood Cell-Derived Extracellular Vesicles Against Liver Diseases.2025International journal of nanomedicineFree full text
  9. Redox-driven hybrid nanoenzyme dynamically activating ferroptosis and disulfidptosis for hepatocellular carcinoma theranostics.2025Journal of colloid and interface science
  10. A Conserved FABP5high Macrophage Subset Promotes Fibrosis and Carcinogenesis in Advanced Liver Disease.2025Liver international : official journal of the International Association for the Study of the LiverFree full text
  11. Hepatic micropeptide modulates mitochondrial RNA processing machinery in hepatocellular carcinoma.2025Molecular cell
  12. A long-term self-driven metronomic photodynamic system for cancer therapy.2025Nature communicationsFree full text
  13. Mendelian randomization and nomogram-based prediction of hepatocellular carcinoma risk in patients with hepatitis B cirrhosis.2025PeerJFree full text
  14. Efficacy and safety of stereotactic body radiotherapy for hepatocellular carcinoma with tumor thrombus in right atrium: a two-center retrospective review.2025Radiation oncology (London, England)Free full text
  15. Multi-omic analysis reveals elevated BRI3BP expression associated with hepatocellular carcinoma progression and poor prognosis.2025Scientific reportsFree full text
  16. Bicarbonate-integrated transarterial chemoembolization (TACE) in real-world hepatocellular carcinoma.2025Signal transduction and targeted therapyFree full text
  17. Pharmacological mechanisms of carvacrol against hepatocellular carcinoma by network pharmacology and molecular docking.2025Technology and health care : official journal of the European Society for Engineering and Medicine
  18. RHEB neddylation by the UBE2F-SAG axis enhances mTORC1 activity and aggravates liver tumorigenesis.2025The EMBO journalFree full text
  19. Autophagy inhibitor-sensitized artificially activated neutrophils against hepatocellular carcinoma.2025TheranosticsFree full text
  20. Modified CEUS LI-RADS With Perfluorobutane in Patients at High-Risk for Hepatocellular Carcinoma: A Systematic Review and Network Meta-Analysis.2025Ultrasound in medicine & biology
  21. Radiomics-based Machine Learning to Predict the Recurrence of Hepatocellular Carcinoma: A Systematic Review and Meta-analysis.2024Academic radiology
  22. Aggregation-induced emission: Application in diagnosis and therapy of hepatocellular carcinoma.2024Biosensors & bioelectronics
  23. Poly(lactic acid hydroxyacetic acid)-poly(ethylene glycol)-modified ginsenoside Rg3 nanomedicine enhances anti-tumor effect in hepatocellular carcinoma.2024Drug development and industrial pharmacy
  24. Subtype-specific human endogenous retrovirus K102 envelope protein is a novel serum immunosuppressive biomarker of cancer.2024Frontiers in immunologyFree full text
  25. Effects of sinomenine on a rat orthotopic liver carcinoma model.2024Histology and histopathology
  26. Transcription Factor E2F1 Enhances Hepatocellular Carcinoma Cell Proliferation and Stemness by Activating GINS1.2024Journal of environmental pathology, toxicology and oncology : official organ of the International Society for Environmental Toxicology and Cancer
  27. Macrophages as Targets in Hepatocellular Carcinoma Therapy.2024Molecular cancer therapeutics
  28. Transcription factor 7 like 2 promotes metastasis in hepatocellular carcinoma via NEDD9-mediated activation of AKT/mTOR signaling pathway.2024Molecular medicine (Cambridge, Mass.)Free full text
  29. A Poly(amino acid)-Based Nanomedicine Strategy: Telomere-Telomerase Axis Targeting and Magnetic Resonance Imaging in Hepatocellular Carcinoma Treatment.2024Nano letters
  30. EphrinB2 drives osteogenic fate of adult cardiac fibroblasts in a calcium influx dependent manner.2023American journal of physiology. Cell physiology
  31. Hepatoid adenocarcinoma-Clinicopathological features and molecular characteristics.2023Cancer letters
  32. Anti-PD-1/PD-L1 immunotherapy in conversion treatment of locally advanced hepatocellular carcinoma.2023Clinical and experimental medicine
  33. Impact of radiation therapy and alpha-fetoprotein level on survival outcomes for patients with hepatocellular carcinoma: A population-based study.2023Clinics and research in hepatology and gastroenterology
  34. Case Report: Cadonilimab-related toxic epidermal necrolysis-like reactions successfully treated with supplemental Adalimumab.2023Frontiers in immunologyFree full text
  35. 5'-tiRNA-Gln inhibits hepatocellular carcinoma progression by repressing translation through the interaction with eukaryotic initiation factor 4A-I.2023Frontiers of medicine
  36. TRPM2 regulates cell cycle through the Ca2+-CaM-CaMKII signaling pathway to promote HCC.2023Hepatology communicationsFree full text
  37. m6A regulator-mediated methylation modification highlights immune infiltration patterns for predicting risk in hepatocellular carcinoma.2023Journal of cancer research and clinical oncologyFree full text
  38. A negative feedback loop between KLF9 and the EMT program dictates metastasis of hepatocellular carcinoma.2023Journal of cellular and molecular medicineFree full text
  39. Evaluation of a Tumor-Targeting Oligosaccharide Nanosystem in BNCT on an Orthotopic Hepatocellular Carcinoma Model.2023Molecular pharmaceutics
  40. Expression and prognostic impact of NTF3 and TrkC in hepatocellular carcinoma.2023Scandinavian journal of gastroenterology
  41. Response to Letter to the Editor Regarding the Article "Contrast-Enhanced Ultrasound Liver Imaging Reporting and Data System in Diagnosing Hepatocellular Carcinoma: Diagnostic Performance and Interobserver Agreement" by Zhou and Collaborato2023Ultraschall in der Medizin (Stuttgart, Germany : 1980)
  42. Identification of Immune-Related Markers in Hepatocellular Carcinoma Based on Gene Co-expression Network.2022Biochemical genetics
  43. Design, synthesis, and biological evaluation of quinazoline derivatives with covalent reversible warheads as potential FGFR4 inhibitors.2022Bioorganic chemistry
  44. Transfer RNA-derived fragment 5'tRF-Gly promotes the development of hepatocellular carcinoma by direct targeting of carcinoembryonic antigen-related cell adhesion molecule 1.2022Cancer scienceFree full text
  45. The synergistic antitumor effect of IL-6 neutralization with NVP-BEZ235 in hepatocellular carcinoma.2022Cell death & diseaseFree full text
  46. Genetic dominance of transforming growth factor-β1 polymorphisms in chronic liver disease.2022Frontiers in immunologyFree full text
  47. Implications of m6A-associated snRNAs in the prognosis and immunotherapeutic responses of hepatocellular carcinoma.2022Frontiers in immunologyFree full text
  48. Nanosecond pulsed electric field interrupts the glycogen metabolism in hepatocellular carcinoma by modifying the osteopontin pathway.2022Hepatobiliary & pancreatic diseases international : HBPD INT
  49. SLPI suppresses hepatocellular carcinoma progression via endoplasmic reticulum stress induced apoptosis.2022International journal of biological sciencesFree full text
  50. Single-cell immune signature for detecting early-stage HCC and early assessing anti-PD-1 immunotherapy efficacy.2022Journal for immunotherapy of cancerRCTFree full text
  51. Treatment of microvascular invasion in hepatocellular carcinoma with drug-loaded nanocomposite platform under synergistic effect of magnetic field/near-infrared light.2022Journal of biomedical materials research. Part B, Applied biomaterials
  52. The role of AURKA/miR-199b-3p in hepatocellular carcinoma cells.2022Journal of clinical laboratory analysisFree full text
  53. Role of m6A RNA methylation in the development of hepatitis B virus-associated hepatocellular carcinoma.2022Journal of gastroenterology and hepatology
  54. Ultra-thin layered double hydroxide-mediated photothermal therapy combine with asynchronous blockade of PD-L1 and NR2F6 inhibit hepatocellular carcinoma.2022Journal of nanobiotechnologyFree full text
  55. Alkalization of cellular pH leads to cancer cell death by disrupting autophagy and mitochondrial function.2022Oncogene
  56. Circulating MicroRNA Panel as a Diagnostic Marker for Hepatocellular Carcinoma.2022The Turkish journal of gastroenterology : the official journal of Turkish Society of GastroenterologyFree full text
  57. Contrast-Enhanced Ultrasound Liver Imaging Reporting and Data System in Diagnosing Hepatocellular Carcinoma: Diagnostic Performance and Interobserver Agreement.2022Ultraschall in der Medizin (Stuttgart, Germany : 1980)
  58. Downregulation of snoRNA SNORA52 and Its Clinical Significance in Hepatocellular Carcinoma.2021BioMed research internationalFree full text
  59. Tadalafil enhances the therapeutic efficacy of BET inhibitors in hepatocellular carcinoma through activating Hippo pathway.2021Biochimica et biophysica acta. Molecular basis of disease
  60. REPLY.2021Hepatology (Baltimore, Md.)
  61. miR-26b enhances the sensitivity of hepatocellular carcinoma to Doxorubicin via USP9X-dependent degradation of p53 and regulation of autophagy.2021International journal of biological sciencesFree full text
  62. Self-amplification of oxidative stress with tumour microenvironment-activatable iron-doped nanoplatform for targeting hepatocellular carcinoma synergistic cascade therapy and diagnosis.2021Journal of nanobiotechnologyFree full text
  63. RNA N6-Methyladenosine Patterns in Hepatocellular Carcinoma Reveal a Distinct Immune Infiltration Landscape and Clinical Significance.2021Medical science monitor : international medical journal of experimental and clinical researchFree full text
  64. CEUS examination of the outcome of radiofrequency ablation of canine prostate lesions.2021Minimally invasive therapy & allied technologies : MITAT : official journal of the Society for Minimally Invasive Therapy
  65. linc‑ROR facilitates hepatocellular carcinoma resistance to doxorubicin by regulating TWIST1‑mediated epithelial‑mesenchymal transition.2021Molecular medicine reportsFree full text
  66. Glycolysis-related gene expression profiling serves as a novel prognosis risk predictor for human hepatocellular carcinoma.2021Scientific reportsFree full text
  67. An independent poor-prognosis subtype of hepatocellular carcinoma based on the tumor microenvironment.2021The Journal of international medical researchFree full text
  68. CT radiomics nomogram for the preoperative prediction of severe post-hepatectomy liver failure in patients with huge (≥ 10 cm) hepatocellular carcinoma.2021World journal of surgical oncologyFree full text
Chinese-language papers (not in the count)3
  1. [New perspective of diagnosis and treatment of hepatocellular carcinoma complicated with portal vein tumor thrombosis].2025Zhonghua wai ke za zhi [Chinese journal of surgery]
  2. [Progress in surgical treatment of hepatocellular carcinoma with tumor thrombus in the inferior vena cava].2023Zhonghua wai ke za zhi [Chinese journal of surgery]
  3. [The clinical value of terminal branches portal vein embolization for hepatocellular carcinoma with insufficient future liver remnant].2021Zhonghua wai ke za zhi [Chinese journal of surgery]
All its trials on ClinicalTrials.gov, any status34
  1. Exploration of Sintilimab + Bevacizumab + AG Chemotherapy as First-Line Treatment for Unresectable Advanced/Metastatic CholangiocarcinomaNot yet recruitingNCT07328802Lead sponsorPhase 2Start 2026-01
  2. A Prospective, Randomized Study of TACE Combined With Sintilimab, Bevacizumab, and Ipilimumab N01 Treating Advanced HCCRecruitingNCT07422753Lead sponsorPhase 2Start 2026-03
  3. Construction and Clinical Validation of a Predictive Model for Postoperative Adjuvant Therapy in Hepatocellular Carcinoma Based on Whole-Slide Digital Pathological Images and Deep LearningRecruitingNCT07417800Lead sponsorStart 2025-11
  4. Study on the Classification of Comprehensive Treatment Effect of Hepatocellular CarcinomaRecruitingNCT06542796Lead sponsorN/AStart 2024-09
  5. Early-stage Detection of Liver Cancer by Proteins in Peripheral BloodRecruitingNCT06544083Lead sponsorStart 2024-02
  6. Stereotactic Body Radiation Therapy for the Safety and Prognosis of Small Intrahepatic Recurrent HCCRecruitingNCT05596630Lead sponsorN/AStart 2023-05
  7. Adjuvant Stereotactic Body Radiotherapy (SBRT) for Hepatocellular Carcinoma After Hepatectomy With Narrow Margin: a Prospective, Multi-center, Randomized Controlled, Open-labelled, Phase III StudyNot yet recruitingNCT05602974Lead sponsorN/AStart 2023-03
  8. Raman Spectroscopy-Based Deep Learning Model for Early Pan-Cancer Early DiagnosisRecruitingNCT06822413Lead sponsorStart 2022-09
  9. RFA Plus Carrizumab vs Carrizumab Alone for HCCRecruitingNCT04150744Lead sponsorPhase 2Start 2020-08
  10. Single-Arm Clinical Study of Icaritin Soft Capsules as Adjuvant Therapy for Hepatocellular Carcinoma Patients at High Risk of Postoperative RecurrenceActive, not recruitingNCT07328828Lead sponsorPhase 2Start 2024-03
  11. the Effect of Nutrition-optimized Prehabilitation on Perioperative Intervention in Primary Liver CarcinomaCompletedNCT06549829Lead sponsorN/AStart 2024-05
  12. Clinical Application of Quantitative Major Imaging Features of CEUS LI-RADSStatus unknownNCT06590948Lead sponsorStart 2024-07
  13. Triple Recipient Strategy Using Split, Domino, and Auxiliary TechniquesCompletedNCT06683820Lead sponsorStart 2023-04
  14. Preoperative Stereotactic Body Radiotherapy (SBRT) Followed by Hepatectomy for Centrally Located Hepatocellular Carcinoma: a Prospective, Single-center, Phase I StudyStatus unknownNCT05598060Lead sponsorN/AStart 2022-11
  15. The Synergistic Effect of Portal Venous Supply Control and Immunotherapy in Hepatocellular CarcinomaStatus unknownNCT05760430Lead sponsorPhase 2Start 2022-12
  16. Identification and Prognostic Value of Key Genes in Hepatocellular CarcinomaStatus unknownNCT05759858Lead sponsorStart 2022-12
  17. Study of TACE Combined With Lenvatinib to Prevent Postoperative Recurrence in Patients With MVI Positive HCCStatus unknownNCT04911959Lead sponsorPhase 1/Phase 2Start 2022-07
  18. Application Value of CEUS Li-RADS in Hepatic Focal Lesions in Patients With Non-high Risk Factors for HCCStatus unknownNCT04920214Lead sponsorStart 2021-01
  19. Comparing SonoVue With Sonazoid Using CEUS-LIRADS in HCCStatus unknownNCT04006275Lead sponsorPhase 3Start 2019-06
  20. Stereotactic Body Radiotherapy and Surgery for Early-stage Hepatocellular CarcinomaStatus unknownNCT03609151Lead sponsorN/AStart 2018-06
  21. Study of PolyIC and PD-1 mAb in Subjects With Unresectable Hepatocellular CarcinomaStatus unknownNCT03732547Lead sponsorPhase 2Start 2018-10
  22. Stereotactic Body Radiotherapy and Microwave Ablation for Recurrent Small Hepatocellular CarcinomaStatus unknownNCT03609268Lead sponsorN/AStart 2018-06
  23. Superb Micro-vascular Imaging for Evaluation of Hepatic LesionsStatus unknownNCT04917354Lead sponsorStart 2017-04
  24. The Efficacy of Hepatectomy or TILA-TACE in Patients With Resectable Hepatocellular CarcinomaStatus unknownNCT03314532Lead sponsorN/AStart 2017-11
  25. TILA-TACE in Treatment of Hepatocellular CarcinomaStatus unknownNCT03910140Lead sponsorN/AStart 2017-11
  26. Stereotactic Body Radiotherapy Based Treatment for Hepatocellular Carcinoma With Extensive Portal Vein Tumor ThrombosisCompletedNCT04966195Lead sponsorN/AStart 2015-12
  27. Postoperative TACE(Transhepatic Arterial Chemotherapy And Embolization) for Patients With Hepatocellular CarcinomaCompletedNCT02109146Lead (inferred)Phase 3Start 2014-03
  28. Multimodal Thermal Therapy With Targeted and Immunotherapy for Untreated Unresectable HCCNot yet recruitingNCT07596134Study siteN/AStart 2026-10
  29. 29-Gene Liver Cancer Subtype and Immunotherapy EffectivenessNot yet recruitingNCT07100236Study siteStart 2025-08
  30. ABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 OverexpressionRecruitingNCT07327034Study sitePhase 2Start 2025-06
  31. CT011 Autologous CAR-T Cells in Patients With Hepatocellular Carcinoma at Risk of Recurrence After Surgical ResectionRecruitingNCT06560827Study sitePhase 1Start 2023-10
  32. A Study to Evaluate Efficacy and Safety of Hepatic Resection for Liver Cancer With PVTT, HVTT or IVCTT After Initial Ate/BevActive, not recruitingNCT04649489Study sitePhase 3Start 2021-04
  33. Huaier Granule for Prevention of Recurrence and Metastasis of Hepatocarcinoma Following Local AblationStatus unknownNCT03356236Study siteStart 2018-04
  34. Hepatocellular Carcinoma Registry in Asia: The INSIGHT RegistryCompletedNCT03233360Study siteStart 2017-04

Run the PubMed searchClinicalTrials.gov

Cancer

Stomach cancer

胃癌

Led 58 of the 9,782 English-language PubMed papers on stomach cancer with an author in mainland China, 2021–2025: 0.6%.

Papers led
58
2021–2025
Trials led
15
any status, ClinicalTrials.gov
Open trials led
6
recruiting or about to
Open trials as a site
7
led by another institution
Papers led per year
2021: 141420212022: 9920222023: 111120232024: 131320242025: 11112025

9 hospitals in Hangzhou for stomach cancer218 hospitals in China for stomach cancer

Open trials with this hospital 13

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Exploratory Study on the Efficacy of Betaine Hydrochloride in Treating Autoimmune Gastritis
    Phase
    N/A
    Started
    2025-01
    Registry
    NCT06881511

    Age 18 years to 80 years (registered criteria)

    Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou

  2. Recruiting
    Transarterial Neoadjuvant Chemotherapy vs.Traditional Intravenous Chemotherapy For Locally Advanced Gastric Cancer With SOX+PD-1
    Phase
    Phase 3
    Started
    2023-03
    Registry
    NCT05593458

    Age 18 years to 75 years (registered criteria)

    Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou

  3. Recruiting
    Study of Comparing of With and Without Sequential Therapy of S-1
    Phase
    Phase 3
    Started
    2023-01
    Registry
    NCT05813015

    Age 18 years to 75 years (registered criteria)

    Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou

  4. Recruiting
    The Relationship Between Scar Formation and ESD Depth in Therapy for Gastric Carcinoma
    Phase
    N/A
    Started
    2022-01
    Registry
    NCT05323929

    Age 18 years to 75 years (registered criteria)

    Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou

  5. Recruiting
    Raman Spectroscopy-Based Deep Learning Model for Early Pan-Cancer Early Diagnosis
    Phase
    Not given
    Started
    2022-09
    Registry
    NCT06822413

    Age not stated (registered criteria)

    Led by Second Affiliated Hospital, Zhejiang University; 3 listed hospitals as study sitesHangzhou, Nanchang, Shanghai

  6. Not yet recruiting
    AI-Assisted Novel rbcDNA Detection for Early Gastric Cancer Diagnosis
    Phase
    Not given
    Started
    2026-09
    Registry
    NCT07782294

    Age 18 years to 75 years (registered criteria)

    Led by Second Affiliated Hospital, Zhejiang University; 2 listed hospitals as study sitesAnyang, Hangzhou, Shanghai

  7. Recruiting
    Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.
    Phase
    Phase 3
    Started
    2026-04
    Registry
    NCT07385703

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 62 listed hospitals as study sitesAnyang, Beijing, Changchun, Changsha, Changzhou, Chengde, Chengdu, Chongqing, Fuzhou, Guangzhou, Haikou, Hangzhou, Hefei, Jinan, Kunming, Lanzhou, Linyi, Luoyang, Nanchang, Nanchong, Nanjing, Qingdao, Shanghai, Shantou, Shenyang, Shijiazhuang, Suzhou, Taiyuan, Tianjin, Urumqi, Wuhan, Xi'an, Xiamen, Xuzhou, Yangzhou, Zhengzhou

  8. Recruiting
    Radical Surgery Versus Non-Surgery in Gastric Cancer Patients With Peritoneal Metastasis After Successful Conversion Therapy
    Phase
    Phase 3
    Started
    2026-12
    Registry
    NCT07789184

    Age 18 years to 70 years (registered criteria)

    Lead sponsor is not a listed hospital; 25 listed hospitals as study sitesBeijing, Changchun, Chongqing, Dalian, Guangzhou, Hangzhou, Jinan, Nanchang, Nanjing, Qingdao, Shanghai, Tianjin, Urumqi, Wuhan, Xi'an

  9. Recruiting
    Real-world Effectiveness and Safety of Trastuzumab Deruxtecan in Patients With Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma in China
    Phase
    Not given
    Started
    2025-02
    Registry
    NCT06846996

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 31 listed hospitals as study sitesBeijing, Changchun, Fuzhou, Guangzhou, Haikou, Hangzhou, Nanjing, Shanghai, Shantou, Shenyang, Taiyuan, Taizhou, Tianjin, Xuzhou, Zhengzhou

  10. Recruiting
    A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
    Phase
    Phase 1/Phase 2
    Started
    2025-08
    Registry
    NCT07070232

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesChongqing, Hangzhou, Tianjin, Wuhan

  11. Recruiting
    A Clinical Trial Targeting CEA Chimeric Antigen Receptor T (CAR-T) for CEA Positive Advanced Malignant Solid Tumors
    Phase
    Phase 1
    Started
    2023-08
    Registry
    NCT06043466

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesHangzhou

  12. Recruiting
    A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors
    Phase
    Phase 1/Phase 2
    Started
    2022-01
    Registry
    NCT05150691

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 34 listed hospitals as study sitesAnyang, Beijing, Bengbu, Changchun, Changsha, Chongqing, Guangzhou, Hangzhou, Hefei, Jinan, Nanning, Shanghai, Shenyang, Shijiazhuang, Tianjin, Wenzhou, Wuhan, Wuxi, Xi'an, Xiamen, Xuzhou, Yantai, Zhengzhou

  13. Not yet recruiting
    Perioperative Chemotherapy Plus Toripalimab for Epstein-Barr Virus-associated Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma
    Phase
    Phase 2
    Started
    2023-07
    Registry
    NCT05970627

    Age 18 years to 80 years (registered criteria)

    Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesHangzhou, Ningbo

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesPeritoneal spread & advanced diseaseEarly detection & endoscopyImmunotherapy & targeted drugs
Departments in papersGastroenterology / hepatologyMedical oncologyPathology / laboratory medicineSurgery (general/hepatobiliary/pancreatic)
Papers it led58
  1. AI-Assisted Detection of Early Gastric Cancer via Visualization of Mucosal Acidity Compromise During Endoscopy.2025Advanced science (Weinheim, Baden-Wurttemberg, Germany)Free full text
  2. Postoperative survival evaluation of patients with Siewert II adenocarcinoma of esophagogastric junction: a population-based study.2025American journal of surgery
  3. Effects of Neoadjuvant Chemotherapy on Early Postoperative Anxiety and Depression in Patients With Gastric Cancer: An Observational Study.2025Annali italiani di chirurgia
  4. Helicobacter pylori reversing the landscape of neoadjuvant immunotherapy for microsatellite stable gastric cancer: a multicenter cohort study.2025BMC medicineFree full text
  5. Artificial Intelligence and Multimodality Data Integration Decipher Tertiary Lymphoid Structure Maturity in Gastric Cancer.2025Cancer research
  6. A real-world study on the characteristics of autoimmune gastritis: A single-center retrospective cohort in China.2025Clinics and research in hepatology and gastroenterology
  7. Gastric SMARCA4-deficient undifferentiated tumors: clinicopathological analysis of two cases in a single center.2025Diagnostic pathologyFree full text
  8. Latent Profile Analysis and Influencing Factors of Fear of Progression in Patients after Endoscopic Submucosal Dissection for Early Gastric Cancer.2025Journal of gastrointestinal cancer
  9. Analysis of the risk of metachronous colorectal cancer and long-term prognosis in patients following gastrectomy for gastric cancer.2025Scientific reportsFree full text
  10. CALCR interaction with ANTXR1 drives gastric tumor growth and metastasis via AKT signaling pathway.2025Scientific reportsFree full text
  11. Ephrin A1 functions as a ligand of EGFR to promote EMT and metastasis in gastric cancer.2025The EMBO journalFree full text
  12. DR30318, a novel tri-specific T cell engager for Claudin 18.2 positive cancers immunotherapy.2024Cancer immunology, immunotherapy : CIIFree full text
  13. Tumor suppressive function of IGF2BP1 in gastric cancer through decreasing MYC.2024Cancer scienceFree full text
  14. Research advances in the molecular classification of gastric cancer.2024Cellular oncology (Dordrecht, Netherlands)Free full text
  15. Causal link between hypothyroidism and gastric cancer risk: insights gained through multivariable Mendelian randomization and mediation analysis.2024Frontiers in endocrinologyFree full text
  16. Gastric cancer in pregnancy: a review.2024Future oncology (London, England)Free full text
  17. Refractory Diarrhea and Gastric Adenocarcinoma, Just a Coincidence?2024Gastroenterology
  18. NOX4 regulates gastric cancer cell invasion and proliferation by increasing ferroptosis sensitivity through regulating ROS.2024International immunopharmacology
  19. Comparison of postoperative survival between early-onset and late-onset adenocarcinoma of esophagogastric junction: a population-based study.2024Journal of gastroenterology and hepatology
  20. Unexpected Multiple Gastrointestinal Cancers in a Patient with Chronic Eosinophilia: A Case Report.2024Journal of gastrointestinal cancer
  21. Identification of oxeiptosis-associated lncRNAs and prognosis-related signature to predict the immune status in gastric cancer.2024MedicineFree full text
  22. Correlation of Neuroendocrine Differentiation with a Distinctively Suppressive Immune Microenvironment in Gastric Cancer.2024NeuroendocrinologyFree full text
  23. Two-sample Mendelian randomization analysis of the relationship between periodontitis and risk of upper gastrointestinal cancers.2024Postgraduate medical journal
  24. Predictive modeling of lower extreme deep vein thrombosis following radical gastrectomy for gastric cancer: based on multiple machine learning methods.2024Scientific reportsFree full text
  25. Influence of Primary Tumor Resection on Survival of Patients With Metastatic Siewert Type II Adenocarcinoma of the Esophagogastric Junction: A Population-Based, Propensity-Matched Analysis.2023Cancer control : journal of the Moffitt Cancer CenterFree full text
  26. Hepatoid adenocarcinoma-Clinicopathological features and molecular characteristics.2023Cancer letters
  27. Single-cell characteristics and malignancy regulation of alpha-fetoprotein-producing gastric cancer.2023Cancer medicineFree full text
  28. Efficacy of PD-1 Inhibitors in First-Line Treatment for Advanced Gastroesophageal Junction and Gastric Cancer by Subgroups: A Systematic Review and Meta-Analysis.2023Chemotherapy
  29. MAPK4 silencing in gastric cancer drives liver metastasis by positive feedback between cancer cells and macrophages.2023Experimental & molecular medicineFree full text
  30. A 5-Year Follow-Up of a Submucosal Tumor in the Stomach.2023Gastroenterology
  31. Single-Cell Profiling of Tumor Immune Microenvironment Reveals Immune Irresponsiveness in Gastric Signet-Ring Cell Carcinoma.2023Gastroenterology
  32. Gastric microbiota in gastric cancer and precancerous stages: Mechanisms of carcinogenesis and clinical value.2023Helicobacter
  33. Switch/Sucrose Non-Fermentable Complex-Deficient Rhabdoid Carcinoma of Stomach: A Rare Case Report and Literature Review.2023International journal of surgical pathology
  34. Diabetes Mellitus and Gastric Cancer: Correlation and Potential Mechanisms.2023Journal of diabetes researchFree full text
  35. Iatrogenic metastasis of gastric adenocarcinoma to the abdomen.2023The Pan African medical journalFree full text
  36. Depletion of C12orf48 inhibits gastric cancer growth and metastasis via up-regulating Poly r(C)-Binding Protein (PCBP) 1.2022BMC cancerFree full text
  37. Effects of different pepsinogen cut offs in the screening of apparently healthy people.2022Clinical chemistry and laboratory medicine
  38. Computed tomography in the size measurement of gastric gastrointestinal stromal tumors: Implication to risk stratification and "wait-and-see" tactics.2022European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  39. A rare gastric lesion: diminutive, well-differentiated, Grade 3, type 3 gastric neuroendocrine tumor with extremely high ki-67 index removed en bloc under endoscopy.2022Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
  40. Adverse effects of low serum lipoprotein cholesterol on the immune microenvironment in gastric cancer: a case‒control study.2022Lipids in health and diseaseFree full text
  41. HER2 protein expression correlates with Lauren classification and P53 in gastric cancer patients.2022MedicineFree full text
  42. HOXC10 indicates poor survival outcome in gastric cancer and promotes G1/S cell cycle transition through transcriptional repression of p21.2022Neoplasma
  43. DeepTI: A deep learning-based framework decoding tumor-immune interactions for precision immunotherapy in oncology.2022SLAS discovery : advancing life sciences R & D
  44. Gastric Metastasis After Tibial Sarcoma Surgery.2022The American journal of gastroenterology
  45. Serum pepsinogen levels in different regions of China and its influencing factors: a multicenter cross-sectional study.2021BMC gastroenterologyFree full text
  46. Identification of the angiogenesis related genes for predicting prognosis of patients with gastric cancer.2021BMC gastroenterologyFree full text
  47. Predictors of Lymph Node Metastasis in Siewert Type II T1 Adenocarcinoma of the Esophagogastric Junction: A Population-Based Study.2021Cancer control : journal of the Moffitt Cancer CenterFree full text
  48. Relationship Between Postoperative Complications and the Prognosis of Gastric Carcinoma Patients Who Underwent Surgical Resection: A Systematic Review and Meta-Analysis.2021Cancer control : journal of the Moffitt Cancer CenterFree full text
  49. A clinical model to predict distant metastasis in patients with superficial gastric cancer with negative lymph node metastasis and a survival analysis for patients with metastasis.2021Cancer medicineFree full text
  50. Gastric mucin phenotype indicates aggressive biological behaviour in early differentiated gastric adenocarcinomas following endoscopic treatment.2021Diagnostic pathologyFree full text
  51. Dynamics of Endocytosis and Degradation of Antibody-Drug Conjugate T-DM1 in HER2 Positive Cancer Cells.2021Drug design, development and therapyFree full text
  52. Current and potential biomarkers in gastric cancer: a critical review of the literature.2021Future oncology (London, England)
  53. A commentary on "Efficacy and safety of short-term (3 days) enoxaparin in preventing venous thromboembolism after gastric cancer surgery: A single-center, prospective cohort study" (Int J Surg 2021; 89:105946).2021International journal of surgery (London, England)
  54. "Sweet tooth"-oriented SN38 prodrug delivery nanoplatform for targeted gastric cancer therapy.2021Journal of materials chemistry. B
  55. Heterogeneity of MSI-H gastric cancer identifies a subtype with worse survival.2021Journal of medical genetics
  56. Prodrug polymeric micelles integrating cancer-associated fibroblasts deactivation and synergistic chemotherapy for gastric cancer.2021Journal of nanobiotechnologyFree full text
  57. Immunotherapies for well-differentiated grade 3 gastroenteropancreatic neuroendocrine tumors: A new category in the World Health Organization classification.2021World journal of gastroenterologyFree full text
  58. Decreased exosome-delivered miR-486-5p is responsible for the peritoneal metastasis of gastric cancer cells by promoting EMT progress.2021World journal of surgical oncologyFree full text
All its trials on ClinicalTrials.gov, any status36
  1. AI-Assisted Novel rbcDNA Detection for Early Gastric Cancer DiagnosisNot yet recruitingNCT07782294Lead sponsorStart 2026-09
  2. Exploratory Study on the Efficacy of Betaine Hydrochloride in Treating Autoimmune GastritisRecruitingNCT06881511Lead sponsorN/AStart 2025-01
  3. The Relationship Between Scar Formation and ESD Depth in Therapy for Gastric CarcinomaRecruitingNCT05323929Lead sponsorN/AStart 2022-01
  4. Raman Spectroscopy-Based Deep Learning Model for Early Pan-Cancer Early DiagnosisRecruitingNCT06822413Lead sponsorStart 2022-09
  5. Electroacupuncture Combined With Paclitaxel Protein-bound and PD-1 Antibody for Second-line Treatment of HER2 Negative, pMMR/MSS Advanced Gastric CancerActive, not recruitingNCT06992024Lead sponsorPhase 2Start 2025-04
  6. taVNS Reduces Postoperative Pain and Complications in Patients With Gastric and Intestinal TumorsCompletedNCT06763913Lead sponsorN/AStart 2025-01
  7. Metabonomics Study of Chronic Gastritis and Gastric CarcinomaStatus unknownNCT04624282Lead sponsorStart 2020-11
  8. Nutrition Education Program for Postoperative Patients With Gastric CancerStatus unknownNCT03952442Lead sponsorN/AStart 2019-02
  9. Intra-arterial Infusion Chemotherapy Combined With Sodium Bicarbonate for Unresectable Gastric CancerStatus unknownNCT03822130Lead sponsorEarly phase 1Start 2019-02
  10. The Research of Constructing a Risk Assessment Model for Gastric Cancer Based on Machine LearningStatus unknownNCT04957407Lead sponsorStart 2019-01
  11. Nasal Endoscopic Screening and Risk Assessment for Early Gastric CancerStatus unknownNCT04989153Lead sponsorStart 2016-03
  12. Transarterial Neoadjuvant Chemotherapy vs.Traditional Intravenous Chemotherapy For Locally Advanced Gastric Cancer With SOX+PD-1RecruitingNCT05593458Lead (inferred)Phase 3Start 2023-03
  13. Study of Comparing of With and Without Sequential Therapy of S-1RecruitingNCT05813015Lead (inferred)Phase 3Start 2023-01
  14. Evaluation of Consistency of PDX Model for Predicting Therapeutic Effect of Gastric CancerStatus unknownNCT05616533Lead (inferred)Start 2023-09
  15. Study of Tislelizumab in Combination With SOX for the Treatment of Gastric Cancer With Liver MetastasesStatus unknownNCT05325528Lead (inferred)Phase 2/Phase 3Start 2022-04
  16. Radical Surgery Versus Non-Surgery in Gastric Cancer Patients With Peritoneal Metastasis After Successful Conversion TherapyRecruitingNCT07789184Study sitePhase 3Start 2026-12
  17. Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.RecruitingNCT07385703Study sitePhase 3Start 2026-04
  18. A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant TumorsRecruitingNCT07070232Study sitePhase 1/Phase 2Start 2025-08
  19. Real-world Effectiveness and Safety of Trastuzumab Deruxtecan in Patients With Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma in ChinaRecruitingNCT06846996Study siteStart 2025-02
  20. Perioperative Chemotherapy Plus Toripalimab for Epstein-Barr Virus-associated Locally Advanced Gastric or Esophagogastric Junction AdenocarcinomaNot yet recruitingNCT05970627Study sitePhase 2Start 2023-07
  21. A Clinical Trial Targeting CEA Chimeric Antigen Receptor T (CAR-T) for CEA Positive Advanced Malignant Solid TumorsRecruitingNCT06043466Study sitePhase 1Start 2023-08
  22. A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid TumorsRecruitingNCT05150691Study sitePhase 1/Phase 2Start 2022-01
  23. Research on Intelligent Screening and Decision-making for Neoadjuvant Therapy in Locally Advanced Gastric Cancer Based on Multi-omics IntegrationStatus unknownNCT06396143Study siteStart 2024-07
  24. Real-World Observational Study to Describe Treatment Patterns in Patients With HER2-Positive Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer in East AsiaCompletedNCT05606094Study siteStart 2023-03
  25. Perioperative Chemotherapy Plus Trastuzumab Plus Toripalimab in HER2 Positive Locally Advanced Gastric or Esophagogastric Junction AdenocarcinomaActive, not recruitingNCT05715931Study sitePhase 2Start 2023-05
  26. Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) OverexpressionCompletedNCT05052801Study sitePhase 3Start 2022-03
  27. Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer.TerminatedNCT05111626Study sitePhase 3Start 2022-03
  28. PD1 Combined With Chemotherapy for Adjuvant Treatment of Gastric CancerActive, not recruitingNCT05180734Study sitePhase 3Start 2022-02
  29. Study of ESG401 in Adults With Solid TumorsCompletedNCT04892342Study sitePhase 1/Phase 2Start 2021-09
  30. Study to Assess the Efficacy and Safety of Lanreotide Autogel® in Chinese Participants With GEP-NETsCompletedNCT04852679Study sitePhase 3Start 2021-05
  31. A Study of RC48-ADC in Local Advanced or Metastatic Gastric Cancer With the HER2-OverexpressionStatus unknownNCT04714190Study sitePhase 3Start 2021-03
  32. A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal CancersActive, not recruitingNCT05152147Study sitePhase 3Start 2021-12
  33. Perioperative Treatment of Combined SOX With Apatinib and Camrelizumab for Oesophagogastric CancerActive, not recruitingNCT04208347Study sitePhase 2/Phase 3Start 2019-12
  34. A Study of Paclitaxel With or Without Ramucirumab (LY3009806) in Participants With Gastric or Gastroesophageal CancerCompletedNCT02898077Study sitePhase 3Start 2017-03
  35. Chemotherapy Alone Versus Surgery Plus Chemotherapy for Distal Gastric Cancer With One Non-curable FactorStatus unknownNCT03399253Study sitePhase 2/Phase 3Start 2017-12
  36. Extensive Intraoperative Peritoneal Lavage After Curative Gastrectomy for Locally Advanced Gastric Cancer (SEIPLUS)CompletedNCT02745509Study siteN/AStart 2016-03

Run the PubMed searchClinicalTrials.gov

Cancer

Retinoblastoma

视网膜母细胞瘤

Led 1 of the 301 English-language PubMed papers on retinoblastoma with an author in mainland China, 2021–2025: 0.3%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

5 hospitals in Hangzhou for retinoblastoma196 hospitals in China for retinoblastoma

No open trial on retinoblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersOphthalmology / neuro-ophthalmology

Run the PubMed searchClinicalTrials.gov

Cancer

Chordoma

脊索瘤

Led no English-language PubMed papers on chordoma in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

1 hospital in Hangzhou for chordoma88 hospitals in China for chordoma

No open trial on chordoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Earlier papers (2016–2020)1
  1. Diagnostic Clues and Treatment of Intradural Cranial Chordoma.2016Chinese medical journal

Run the PubMed searchClinicalTrials.gov

Cancer

Osteosarcoma

骨肉瘤

Led 16 of the 2,257 English-language PubMed papers on osteosarcoma with an author in mainland China, 2021–2025: 0.7%.

Papers led
16
2021–2025
Trials led
5
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 4420212022: 3320222023: 3320232024: 3320242025: 332025

22 hospitals in Hangzhou for osteosarcoma742 hospitals in China for osteosarcoma

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    ARTEMIS-002: HS-20093 in Patients With Relapsed or Refractory Osteosarcoma and Other Sarcomas
    Phase
    Phase 2
    Started
    2023-06
    Registry
    NCT05830123

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 11 listed hospitals as study sitesBeijing, Changsha, Guangzhou, Hangzhou, Shanghai, Tianjin, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers

Over half of these papers are lab or animal studies.

Papers it led16
  1. Soluble immune checkpoint factors reveal high-risk osteosarcoma subtypes and enable early metastasis prediction.2025Frontiers in immunology
  2. Immune-related glycosylation genes based classification predicts prognosis and therapy options of osteosarcoma.2025Gene
  3. HSP47 inhibition-induced CD155 expression through TRAF2 deubiquitination promotes tumor immune evasion.2025Journal for immunotherapy of cancer
  4. PSMD14 is a novel prognostic marker and therapeutic target in osteosarcoma.2024Diagnostic pathology
  5. Investigating the synergy of Shikonin and Valproic acid in inducing apoptosis of osteosarcoma cells via ROS-mediated EGR1 expression.2024Phytomedicine : international journal of phytotherapy and phytopharmacology
  6. Small Nuclear Ribonucleoprotein Polypeptides B and B1 Promote Osteosarcoma Progression via Activating the Ataxia-Telangiectasia Mutated Signaling Pathway through Ribonucleotide Reductase Subunit M2.2024The American journal of pathology
  7. Human γδ T cells induce CD8+ T cell antitumor responses via antigen-presenting effect through HSP90-MyD88-mediated activation of JNK.2023Cancer immunology, immunotherapy : CII
  8. Cancer cells reprogram to metastatic state through the acquisition of platelet mitochondria.2023Cell reports
  9. Chitosan oligosaccharide suppresses osteosarcoma malignancy by inhibiting CEMIP via the PI3K/AKT/mTOR pathway.2023Medical oncology (Northwood, London, England)
  10. Mitochondria-Targeting Polymer Micelle of Dichloroacetate Induced Pyroptosis to Enhance Osteosarcoma Immunotherapy.2022ACS nano
  11. Metabolic control of CD47 expression through LAT2-mediated amino acid uptake promotes tumor immune evasion.2022Nature communications
  12. MerTK-mediated efferocytosis promotes immune tolerance and tumor progression in osteosarcoma through enhancing M2 polarization and PD-L1 expression.2022Oncoimmunology
  13. Transcription factor ELK1 accelerates aerobic glycolysis to enhance osteosarcoma chemoresistance through miR-134/PTBP1 signaling cascade.2021Aging
  14. Cell Differentiation Trajectory-Associated Molecular Classification of Osteosarcoma.2021Genes
  15. Exploration of Immune-Related Gene Expression in Osteosarcoma and Association With Outcomes.2021JAMA network open
  16. A panel of eight mRNA signatures improves prognosis prediction of osteosarcoma patients.2021Medicine
Earlier papers (2016–2020)36
  1. 2-methylbenzoyl berbamine, a multi-targeted inhibitor, suppresses the growth of human osteosarcoma through disabling NF-κB, ERK and AKT signaling networks.2020Aging
  2. Water extract of sporoderm-broken spores of Ganoderma lucidum enhanced pd-l1 antibody efficiency through downregulation and relieved complications of pd-l1 monoclonal antibody.2020Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
  3. TFAP2C-mediated LINC00922 signaling underpins doxorubicin-resistant osteosarcoma.2020Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
  4. The multiple function of long noncoding RNAs in osteosarcoma progression, drug resistance and prognosis.2020Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
  5. A Delta-radiomics model for preoperative evaluation of Neoadjuvant chemotherapy response in high-grade osteosarcoma.2020Cancer imaging : the official publication of the International Cancer Imaging Society
  6. Andrographolide induces apoptosis in human osteosarcoma cells via the ROS/JNK pathway.2020International journal of oncology
  7. Estrogen receptor β induces autophagy of osteosarcoma through the mTOR signaling pathway.2020Journal of orthopaedic surgery and research
  8. Autophagy inhibitor enhance ZnPc/BSA nanoparticle induced photodynamic therapy by suppressing PD-L1 expression in osteosarcoma immunotherapy.2019Biomaterials
  9. Innate Immune Cells: A Potential and Promising Cell Population for Treating Osteosarcoma.2019Frontiers in immunology
  10. Inflammatory responses and biological characteristics of human osteosarcoma cells and umbilical cord blood mononuclear cells in co-cultured microenvironment.2019Journal of biological regulators and homeostatic agents
  11. Anti-CD166/4-1BB chimeric antigen receptor T cell therapy for the treatment of osteosarcoma.2019Journal of experimental & clinical cancer research : CR
  12. Functional Genetic Single-Nucleotide Polymorphisms (SNPs) in Cyclin-Dependent Kinase Inhibitor 2A/B (CDKN2A/B) Locus Are Associated with Risk and Prognosis of Osteosarcoma in Chinese Populations.2019Medical science monitor : international medical journal of experimental and clinical research
  13. Molecular mechanisms of estrogen receptor β-induced apoptosis and autophagy in tumors: implication for treating osteosarcoma.2019The Journal of international medical research
  14. Epigenetic Regulation of CXCL12 Plays a Critical Role in Mediating Tumor Progression and the Immune Response In Osteosarcoma.2018Cancer research
  15. PARK2 inhibits osteosarcoma cell growth through the JAK2/STAT3/VEGF signaling pathway.2018Cell death & disease
  16. MicroRNA-330-3p Expression Indicates Good Prognosis and Suppresses Cell Proliferation by Targeting Bmi-1 in Osteosarcoma.2018Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology
  17. Survival Prediction in High-grade Osteosarcoma Using Radiomics of Diagnostic Computed Tomography.2018EBioMedicine
  18. Decitabine Enhances Vγ9Vδ2 T Cell-Mediated Cytotoxic Effects on Osteosarcoma Cells via the NKG2DL-NKG2D Axis.2018Frontiers in immunology
  19. Valproic Acid Combined with Zoledronate Enhance γδ T Cell-Mediated Cytotoxicity against Osteosarcoma Cells via the Accumulation of Mevalonate Pathway Intermediates.2018Frontiers in immunology
  20. Melatonin inhibits osteosarcoma stem cells by suppressing SOX9-mediated signaling.2018Life sciences
  21. Clinical Features and Prognostic Factors in Elderly Ewing Sarcoma Patients.2018Medical science monitor : international medical journal of experimental and clinical research
  22. Cantharidin Inhibits Anti-Apoptotic Bcl-2 Family Proteins and Induces Apoptosis in Human Osteosarcoma Cell Lines MG-63 and MNNG/HOS via Mitochondria-Dependent Pathway.2018Medical science monitor : international medical journal of experimental and clinical research
  23. Meta-analysis of serum lactate dehydrogenase and prognosis for osteosarcoma.2018Medicine
  24. Paeoniflorin induces G2/M cell cycle arrest and caspase-dependent apoptosis through the upregulation of Bcl-2 X-associated protein and downregulation of B-cell lymphoma 2 in human osteosarcoma cells.2018Molecular medicine reports
  25. Zinc phthalocyanine encapsulated in polymer micelles as a potent photosensitizer for the photodynamic therapy of osteosarcoma.2018Nanomedicine : nanotechnology, biology, and medicine
  26. Combination therapy with L-arginine and α-PD-L1 antibody boosts immune response against osteosarcoma in immunocompetent mice.2017Cancer biology & therapy
  27. Escin induces caspase-dependent apoptosis and autophagy through the ROS/p38 MAPK signalling pathway in human osteosarcoma cells in vitro and in vivo.2017Cell death & disease
  28. Endostar combined with chemotherapy in a pediatric osteosarcoma with pulmonary metastasis and malignant pleural effusion: A case report.2017Medicine
  29. Three hematological indexes that may serve as prognostic indicators in patients with primary, high-grade, appendicular osteosarcoma.2017Oncotarget
  30. A review and outlook in the treatment of osteosarcoma and other deep tumors with photodynamic therapy: from basic to deep.2017Oncotarget
  31. Overendocytosis of superparamagnetic iron oxide particles increases apoptosis and triggers autophagic cell death in human osteosarcoma cell under a spinning magnetic field.2017Oncotarget
  32. Bio-inspired cisplatin nanocarriers for osteosarcoma treatment.2016Biomaterials science
  33. MicroRNA-133a Inhibits Osteosarcoma Cells Proliferation and Invasion via Targeting IGF-1R.2016Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology
  34. The role of CTLA-4 and PD-1 in anti-tumor immune response and their potential efficacy against osteosarcoma.2016International immunopharmacology
  35. Sinomenine prevents metastasis of human osteosarcoma cells via S phase arrest and suppression of tumor-related neovascularization and osteolysis through the CXCR4-STAT3 pathway.2016International journal of oncology
  36. SIRT1 promotes metastasis of human osteosarcoma cells.2016Oncotarget
All its trials on ClinicalTrials.gov, any status6
  1. A Clinical Study of Surufatinib Combined With Chemotherapy as Neoadjuvant Treatment in OsteosarcomaStatus unknownNCT05926492Lead sponsorPhase 2Start 2024-01
  2. A Study of Sulfatinib on Relapsed or Refractory Drug Resistant OsteosarcomaNot yet recruitingNCT05590572Lead sponsorPhase 1/Phase 2Start 2023-01
  3. Evaluation of Myocardial Injury After Anthracycline Chemotherapy in Osteosarcoma Patients Using CMRStatus unknownNCT04461223Lead sponsorStart 2019-12
  4. Proteomics Research of OsteosarcomaStatus unknownNCT03932058Lead sponsorStart 2018-09
  5. Zoledronic Acid in Decrease the Lung Metastatic Rate of OsteosarcomaStatus unknownNCT03932071Lead sponsorPhase 4Start 2017-01
  6. ARTEMIS-002: HS-20093 in Patients With Relapsed or Refractory Osteosarcoma and Other SarcomasRecruitingNCT05830123Study sitePhase 2Start 2023-06

Run the PubMed searchClinicalTrials.gov

Cancer

Gastrointestinal stromal tumour

胃肠道间质瘤

Led 4 of the 523 English-language PubMed papers on gastrointestinal stromal tumour with an author in mainland China, 2021–2025: 0.8%.

Papers led
4
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 2220222023: 2220232024: 0020242025: 002025

16 hospitals in Hangzhou for gastrointestinal stromal tumour261 hospitals in China for gastrointestinal stromal tumour

No open trial on gastrointestinal stromal tumour lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersRadiology / nuclear medicineGastroenterology / hepatology
Papers it led4
  1. A CT-based nomogram established for differentiating gastrointestinal heterotopic pancreas from gastrointestinal stromal tumor: compared with a machine-learning model.2023BMC medical imaging
  2. Duodenal neuroendocrine neoplasms on enhanced CT: establishing a diagnostic model with duodenal gastrointestinal stromal tumors in the non-ampullary area and analyzing the value of predicting prognosis.2023Journal of cancer research and clinical oncology
  3. Building contrast-enhanced CT-based models for preoperatively predicting malignant potential and Ki67 expression of small intestine gastrointestinal stromal tumors (GISTs).2022Abdominal radiology (New York)
  4. Computed tomography in the size measurement of gastric gastrointestinal stromal tumors: Implication to risk stratification and "wait-and-see" tactics.2022European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
Earlier papers (2016–2020)7
  1. MicroRNA-30a targets BECLIN-1 to inactivate autophagy and sensitizes gastrointestinal stromal tumor cells to imatinib.2020Cell death & disease
  2. Endoscopic or laparoscopic resection for small gastrointestinal stromal tumors: a cumulative meta-analysis.2020Chinese medical journal
  3. Diffuse primary extra-gastrointestinal stromal tumor of the peritoneum: A rare case report.2020Medicine
  4. Prevalence, diagnosis, and treatment of primary hepatic gastrointestinal stromal tumors.2020World journal of gastroenterology
  5. Resection of GIST in the duodenum and proximal jejunum: A retrospective analysis of outcomes.2019European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  6. Mesenteric fibromatosis after resection for gastrointestinal stromal tumor of stomach: A case report.2017Medicine
  7. [A case of neurofibromatosis complicated with small bowel obstruction].2016Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences

Run the PubMed searchClinicalTrials.gov

Cancer

Neuroblastoma

神经母细胞瘤

Led 3 of the 1,132 English-language PubMed papers on neuroblastoma with an author in mainland China, 2021–2025: 0.3%.

Papers led
3
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 1120232024: 1120242025: 002025

8 hospitals in Hangzhou for neuroblastoma352 hospitals in China for neuroblastoma

No open trial on neuroblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNeurology

Run the PubMed searchClinicalTrials.gov

Cancer

Ewing sarcoma

尤文肉瘤

Led no English-language PubMed papers on Ewing sarcoma in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

6 hospitals in Hangzhou for Ewing sarcoma139 hospitals in China for Ewing sarcoma

No open trial on Ewing sarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Earlier papers (2016–2020)1
  1. Clinical Features and Prognostic Factors in Elderly Ewing Sarcoma Patients.2018Medical science monitor : international medical journal of experimental and clinical research
All its trials on ClinicalTrials.gov, any status1
  1. A Clinical Study of TK216 in Patients With Relapsed or Refractory Ewing's SarcomaCompletedNCT05046314Study sitePhase 2Start 2024-03

Run the PubMed searchClinicalTrials.gov

Blood disorders

Multiple myeloma

多发性骨髓瘤

Led 5 of the 1,676 English-language PubMed papers on multiple myeloma with an author in mainland China, 2021–2025: 0.3%.

Papers led
5
2021–2025
Trials led
3
any status, ClinicalTrials.gov
Open trials led
2
recruiting or about to
Open trials as a site
3
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 1120232024: 2220242025: 112025

9 hospitals in Hangzhou for multiple myeloma178 hospitals in China for multiple myeloma

Open trials with this hospital 5

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Novel CD19/BCMA Dual-Targeted CAR-T Cell Therapy for the Treatment of Relapsed/Refractory Multiple Myeloma
    Phase
    N/A
    Started
    2025-11
    Registry
    NCT07359014

    Age 18 years to 75 years (registered criteria)

    Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou

  2. Recruiting
    Ixazomib Plus Low-dose Lenalidomide Versus Ixazomib Alone for Maintenance Treatment of High Risk Multiple Myeloma
    Phase
    Phase 4
    Started
    2022-07
    Registry
    NCT05722405

    Age 18 years to 80 years (registered criteria)

    Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou

  3. Recruiting
    To Evaluate the Safety of SG2918 in Patients With Relapsed/Refractory Multiple Myeloma
    Phase
    Phase 1/Phase 2
    Started
    2026-04
    Registry
    NCT07454187

    Age 18 years to 80 years (registered criteria)

    Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesHangzhou, Suzhou, Xi'an, Zhengzhou

  4. Recruiting
    A Clinical Study Comparing SG301 Plus Pomalidomide and Dexamethasone to Placebo Plus Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma Patients
    Phase
    Phase 3
    Started
    2024-06
    Registry
    NCT06508983

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 9 listed hospitals as study sitesBeijing, Guangzhou, Hangzhou, Suzhou, Tianjin, Wuhan, Xi'an, Zhengzhou

  5. Recruiting
    A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
    Phase
    Phase 3
    Started
    2022-10
    Registry
    NCT05552222

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 29 listed hospitals as study sitesBeijing, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Jinan, Nanchang, Nanjing, Nanning, Shanghai, Shenyang, Shenzhen, Tianjin, Wenzhou, Wuhan, Xi'an, Xiamen, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesDrug combinationsCAR-T & cell therapyRelapse & resistance
Departments in papersMedical oncologyRadiology / nuclear medicine
Papers it led5
  1. CD27-Armored BCMA CAR T-cell Therapy (CBG-002) for Relapsed and Refractory Multiple Myeloma: A Phase I Clinical Trial.2025Cancer immunology research
  2. Using protein turnover assay to explore the drug mechanism of Carfilzomib.2024Acta biochimica et biophysica SinicaFree full text
  3. Global, regional, and national burden and quality of care of multiple myeloma, 1990-2019.2024Journal of global healthFree full text
  4. New diagnostic strategy for multiple myeloma: A review.2023MedicineFree full text
  5. (-)-Epigallocatechin-3-gallate plays an antagonistic role in the antitumor effect of bortezomib in myeloma cells via activating Wnt/β-catenin signaling pathway.2022Advances in clinical and experimental medicine : official organ Wroclaw Medical University
All its trials on ClinicalTrials.gov, any status10
  1. Novel CD19/BCMA Dual-Targeted CAR-T Cell Therapy for the Treatment of Relapsed/Refractory Multiple MyelomaRecruitingNCT07359014Lead sponsorN/AStart 2025-11
  2. Ixazomib Plus Low-dose Lenalidomide Versus Ixazomib Alone for Maintenance Treatment of High Risk Multiple MyelomaRecruitingNCT05722405Lead sponsorPhase 4Start 2022-07
  3. Novel BCMA-targeted CAR-T Cell Therapy for Multiple MyelomaStatus unknownNCT04706936Lead sponsorPhase 1Start 2021-04
  4. To Evaluate the Safety of SG2918 in Patients With Relapsed/Refractory Multiple MyelomaRecruitingNCT07454187Study sitePhase 1/Phase 2Start 2026-04
  5. A Clinical Study Comparing SG301 Plus Pomalidomide and Dexamethasone to Placebo Plus Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma PatientsRecruitingNCT06508983Study sitePhase 3Start 2024-06
  6. A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple MyelomaRecruitingNCT05552222Study sitePhase 3Start 2022-10
  7. A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and LenalidomideActive, not recruitingNCT06208150Study sitePhase 3Start 2024-01
  8. A Phase III Study of Eque-cel in Subjects With Len-refractory RRMM (FUMANBA-03)Active, not recruitingNCT06464991Study sitePhase 3Start 2024-03
  9. SG301 Safety Study in Subjects With Relapsed or Refractory Multiple Myeloma and Other Hematological MalignanciesActive, not recruitingNCT04684108Study sitePhase 1Start 2021-11
  10. APG-2575 Monotherapy or in Combination With Lenalidomide/DXMS in Subjects With Relapsed or Refractory Multiple MyelomaStatus unknownNCT04674514Study sitePhase 1/Phase 2Start 2021-04

Run the PubMed searchClinicalTrials.gov

Blood disorders

Haemophagocytic lymphohistiocytosis

噬血细胞性淋巴组织细胞增生症

Led 2 of the 399 English-language PubMed papers on haemophagocytic lymphohistiocytosis with an author in mainland China, 2021–2025: 0.5%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 1120242025: 002025

4 hospitals in Hangzhou for haemophagocytic lymphohistiocytosis66 hospitals in China for haemophagocytic lymphohistiocytosis

No open trial on haemophagocytic lymphohistiocytosis lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesTreatment regimensGenetics & inherited forms
Departments in papersRheumatology & immunologyNeurosurgery

Run the PubMed searchClinicalTrials.gov

Blood disorders

Thrombotic thrombocytopenic purpura

血栓性血小板减少性紫癜

Led 1 of the 64 English-language PubMed papers on thrombotic thrombocytopenic purpura with an author in mainland China, 2021–2025: 1.6%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

5 hospitals in Hangzhou for thrombotic thrombocytopenic purpura59 hospitals in China for thrombotic thrombocytopenic purpura

No open trial on thrombotic thrombocytopenic purpura lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Neuromyelitis optica spectrum disorder

视神经脊髓炎谱系疾病

Led 7 of the 485 English-language PubMed papers on neuromyelitis optica spectrum disorder with an author in mainland China, 2021–2025: 1.4%.

Papers led
7
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 3320212022: 3320222023: 1120232024: 0020242025: 002025

3 hospitals in Hangzhou for neuromyelitis optica spectrum disorder67 hospitals in China for neuromyelitis optica spectrum disorder

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Clinical Study of B001 Injection in the Treatment of Neuromyelitis Optica Spectrum Disorders(NMOSD)
    Phase
    Phase 2/Phase 3
    Started
    2024-07
    Registry
    NCT06413654

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 27 listed hospitals as study sitesBeijing, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Kunming, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Wenzhou, Wuhan, Xiamen, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesAntibodies & diagnosisPregnancy, children, older adultsOptic nerve & vision
Departments in papersNeurology
Papers it led7
  1. Aquaporin 4 antibody-positive neuromyelitis optica spectrum disorder with cholangiocarcinoma: Casual or causal association?2023CNS neuroscience & therapeuticsFree full text
  2. Seizures and epilepsy in multiple sclerosis, aquaporin 4 antibody-positive neuromyelitis optica spectrum disorder, and myelin oligodendrocyte glycoprotein antibody-associated disease.2022Epilepsia
  3. Case Report: Neuromyelitis Optica Spectrum Disorder With Progressive Elevation of Cerebrospinal Fluid Cell Count and Protein Level Mimicking Infectious Meningomyelitis: A Diagnostic Challenge.2022Frontiers in immunologyFree full text
  4. Late-onset neuromyelitis optica spectrum disorder mimicking stroke in an elderly Chinese man: Case report.2022The journal of spinal cord medicineFree full text
  5. Neuromyelitis optica spectrum disorder complicated with Sjögren's syndrome: first pediatric case responsive to mycophenolate mofetil treatment.2021Acta neurologica Belgica
  6. Common genetic variants in PRRC2A are associated with both neuromyelitis optica spectrum disorder and multiple sclerosis in Han Chinese population.2021Journal of neurology
  7. Evaluation of brain and spinal cord lesion distribution criteria at disease onset in distinguishing NMOSD from MS and MOG antibody-associated disorder.2021Multiple sclerosis (Houndmills, Basingstoke, England)
All its trials on ClinicalTrials.gov, any status2
  1. A Clinical Study of B001 Injection in the Treatment of Neuromyelitis Optica Spectrum Disorders(NMOSD)RecruitingNCT06413654Study sitePhase 2/Phase 3Start 2024-07
  2. A Study of LP-168 in Healthy VolunteersCompletedNCT05432713Study sitePhase 1Start 2022-05
More papers found outside PubMed (not counted)2
  1. Choroid Plexus Cysts on 7T MRI Differentiate NMOSD from MS2025medRxivpreprint
  2. Criteria for myelin oligodendrocyte glycoprotein antibody‐associated disease: Balancing underdiagnosis with overdiagnosis2023Clinical and Translational Discoveryarticle

Run the PubMed searchClinicalTrials.gov

Other diseases

Myasthenia gravis

重症肌无力

Led 4 of the 499 English-language PubMed papers on myasthenia gravis with an author in mainland China, 2021–2025: 0.8%.

Papers led
4
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 3320242025: 112025

6 hospitals in Hangzhou for myasthenia gravis93 hospitals in China for myasthenia gravis

No open trial on myasthenia gravis lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesThymus & thymectomyAntibodies & diagnosis
Departments in papersNeurologyRadiology / nuclear medicine

Run the PubMed searchClinicalTrials.gov

Other diseases

Moyamoya disease

烟雾病

Led 12 of the 356 English-language PubMed papers on moyamoya disease with an author in mainland China, 2021–2025: 3.4%.

Papers led
12
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 1120212022: 1120222023: 2220232024: 6620242025: 112025

1 hospital in Hangzhou for moyamoya disease47 hospitals in China for moyamoya disease

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Development and Validation of Risk Prediction Models for Stroke and Cognitive Impairment in Moyamoya Disease and Moyamoya Syndrome
    Phase
    Not given
    Started
    2026-08
    Registry
    NCT07894107

    Age 12 years to 70 years (registered criteria)

    Led by Beijing Tiantan Hospital; 12 listed hospitals as study sitesBeijing, Chengdu, Hangzhou, Nanchang, Shanghai, Suzhou, Wuhan, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesImaging & blood flowRevascularisation surgeryChildren
Departments in papersRadiology / nuclear medicineNeurosurgeryNeurology
Papers it led12
  1. Unraveling the links between intracranial artery stenosis, cerebral perfusion, and white matter hyperintensity in moyamoya disease.2026European radiology
  2. Glymphatic dysfunction in moyamoya disease: The influence of arterial stenosis and ventricular enlargement.2025NeuroImage
  3. White matter hyperintensities in cholinergic pathways correlates of cognitive impairment in moyamoya disease.2024European radiology
  4. Glymphatic System Impairment in the Advanced Stage of Moyamoya Disease.2024Journal of neuroscience research
  5. Exploring the Impact of Hemoglobin on Cerebral Blood Flow in Arterial Territories and Surgical Outcomes: Potential Implications for Moyamoya Disease Treatment.2024Journal of the American Heart AssociationFree full text
  6. The effects of anastomoses between anterior and posterior circulation on postoperative prognosis of patients with moyamoya disease.2024Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical NeurophysiologyFree full text
  7. Altered neurovascular coupling and structure-function coupling in Moyamoya disease affect postoperative collateral formation.2024Scientific reportsFree full text
  8. Hemodynamic Effects of Tortuosity and Stenosis in Superficial Temporal Artery-Middle Cerebral Artery Bypass for Moyamoya Disease.2024World neurosurgery
  9. Efficacy assessment of superficial temporal artery-middle cerebral artery bypass surgery in treating moyamoya disease from a hemodynamic perspective: a pilot study using computational modeling and perfusion imaging.2023Acta neurochirurgica
  10. Preoperative Brain Functional Connectivity Improve Predictive Accuracy of Outcomes After Revascularization in Moyamoya Disease.2023NeurosurgeryFree full text
  11. Abnormal brain functional and structural connectivity between the left supplementary motor area and inferior frontal gyrus in moyamoya disease.2022BMC neurologyFree full text
  12. Comparison of Operative and Conservative Treatment for Asymptomatic Moyamoya Disease: Preliminary Experience in Small Retrospective Series.2021World neurosurgery
All its trials on ClinicalTrials.gov, any status1
  1. Development and Validation of Risk Prediction Models for Stroke and Cognitive Impairment in Moyamoya Disease and Moyamoya SyndromeRecruitingNCT07894107Study siteStart 2026-08

Run the PubMed searchClinicalTrials.gov

Other diseases

Wilson disease

肝豆状核变性(Wilson 病)

Led 8 of the 201 English-language PubMed papers on Wilson disease with an author in mainland China, 2021–2025: 4.0%.

Papers led
8
2021–2025
Trials led
4
any status, ClinicalTrials.gov
Open trials led
2
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 3320212022: 2220222023: 2220232024: 0020242025: 112025

3 hospitals in Hangzhou for Wilson disease28 hospitals in China for Wilson disease

Open trials with this hospital 3

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Role for Biochemical Assays and Kayser-Fleischer Rings in Diagnosis of Wilson Disease
    Phase
    Not given
    Started
    2004-01
    Registry
    NCT04965545

    Age 6 years to 65 years (registered criteria)

    Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou

  2. Recruiting
    Clinical Features and Outcome in Patients With Osseomuscular Type of Wilson's Disease
    Phase
    Not given
    Started
    2004-01
    Registry
    NCT04965558

    Age 6 years to 65 years (registered criteria)

    Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou

  3. Recruiting
    Trientine Tetrahydrochloride Administered Once a Day for the First Line Treatment of Wilson's Disease Patients.
    Phase
    Phase 3
    Started
    2026-09
    Registry
    NCT07465718

    Age 8 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Hangzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesGenetics (ATP7B)Diagnosis & copper testsTreatment (chelation, zinc)
Departments in papersNeurology
Papers it led8
  1. Neuroimaging correlates of genetics in patients with Wilson's disease.2025Cerebral cortex (New York, N.Y. : 1991)
  2. Structures of the human Wilson disease copper transporter ATP7B.2023Cell reports
  3. Pathogenicity of Intronic and Synonymous Variants of ATP7B in Wilson Disease.2023The Journal of molecular diagnostics : JMD
  4. Emerging neurological symptoms after liver transplantation: A 6-year follow-up of an adolescent patient with Wilson's disease.2022CNS neuroscience & therapeuticsFree full text
  5. Serum Neurofilament Light Chain in Wilson's Disease: A Promising Indicator but Unparallel to Real-Time Treatment Response.2022Movement disorders : official journal of the Movement Disorder Society
  6. Role for Biochemical Assays and Kayser-Fleischer Rings in Diagnosis of Wilson's Disease.2021Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
  7. Prevalent Pathogenic Variants of ATP7B in Chinese Patients with Wilson's Disease: Geographical Distribution and Founder Effect.2021GenesFree full text
  8. Challenges and suggestions for precise diagnosis and treatment of Wilson's disease.2021World journal of pediatrics : WJP
All its trials on ClinicalTrials.gov, any status5
  1. Clinical Features and Outcome in Patients With Osseomuscular Type of Wilson's DiseaseRecruitingNCT04965558Lead sponsorStart 2004-01
  2. Role for Biochemical Assays and Kayser-Fleischer Rings in Diagnosis of Wilson DiseaseRecruitingNCT04965545Lead sponsorStart 2004-01
  3. The Individual Therapy for Patients With Wilson's DiseaseStatus unknownNCT03957720Lead sponsorEarly phase 1Start 2019-03
  4. Clinical Features and Outcome of Wilson's Disease With Generalized Epilepsy in Chinese PatientsCompletedNCT04965571Lead sponsorStart 2010-09
  5. Trientine Tetrahydrochloride Administered Once a Day for the First Line Treatment of Wilson's Disease Patients.RecruitingNCT07465718Study sitePhase 3Start 2026-09

Run the PubMed searchClinicalTrials.gov

Other diseases

Anti-NMDA receptor encephalitis

抗 NMDA 受体脑炎

Led 4 of the 264 English-language PubMed papers on anti-NMDA receptor encephalitis with an author in mainland China, 2021–2025: 1.5%.

Papers led
4
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 1120222023: 0020232024: 2220242025: 002025

6 hospitals in Hangzhou for anti-NMDA receptor encephalitis126 hospitals in China for anti-NMDA receptor encephalitis

No open trial on anti-NMDA receptor encephalitis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNeurology

Run the PubMed searchClinicalTrials.gov

Other diseases

Takayasu arteritis

大动脉炎

Led no English-language PubMed papers on Takayasu arteritis in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

3 hospitals in Hangzhou for Takayasu arteritis108 hospitals in China for Takayasu arteritis

No open trial on Takayasu arteritis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
All its trials on ClinicalTrials.gov, any status2
  1. A Registry Study Assessing PRO, Dosing Patterns, and Safety of Vunakizumab in Patients With General Rheumatic Diseases.Not yet recruitingNCT06766552Lead sponsorStart 2025-01
  2. Efficacy and Safety of Vunakizumab and Ivarmacitinib in the Treatment of Active Takayasu's ArteritisNot yet recruitingNCT07451665Study sitePhase 4Start 2026-04

Run the PubMed searchClinicalTrials.gov

Other diseases

Idiopathic pulmonary fibrosis

特发性肺纤维化

Led 4 of the 989 English-language PubMed papers on idiopathic pulmonary fibrosis with an author in mainland China, 2021–2025: 0.4%.

Papers led
4
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 332025

9 hospitals in Hangzhou for idiopathic pulmonary fibrosis333 hospitals in China for idiopathic pulmonary fibrosis

No open trial on idiopathic pulmonary fibrosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Amyotrophic lateral sclerosis

肌萎缩侧索硬化症

Led 6 of the 779 English-language PubMed papers on amyotrophic lateral sclerosis with an author in mainland China, 2021–2025: 0.8%.

Papers led
6
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 2220212022: 0020222023: 2220232024: 2220242025: 002025

11 hospitals in Hangzhou for amyotrophic lateral sclerosis194 hospitals in China for amyotrophic lateral sclerosis

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RAG-17 in Subjects With Amyotrophic Lateral Sclerosis (ALS) With Superoxide Dismutase Type 1 (SOD1) Gene Mutation
    Phase
    Phase 1
    Started
    2024-12
    Registry
    NCT06556394

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Chengdu, Hangzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersNeurologyMedical oncology

Over half of these papers are lab or animal studies.

Papers it led6
  1. Clinical characterization and founder effect analysis in Chinese amyotrophic lateral sclerosis patients with SOD1 common variants.2024Annals of medicine
  2. FUS reads histone H3K36me3 to regulate alternative polyadenylation.2024Nucleic acids research
  3. Clinical feature difference between juvenile amyotrophic lateral sclerosis with SPTLC1 and FUS mutations.2023Chinese medical journal
  4. Pathogenicity classification of SOD1 variants of uncertain significance by in vitro aggregation propensity.2023Neurobiology of aging
  5. Taste loss as the sole presenting symptom in Chinese patient with facial onset sensory and motor neuronopathy.2021CNS neuroscience & therapeutics
  6. Aberrant Stress Granule Dynamics and Aggrephagy in ALS Pathogenesis.2021Cells
Earlier papers (2016–2020)2
  1. Sensory nerve disturbance in amyotrophic lateral sclerosis.2018Life sciences
  2. Amyotrophic Lateral Sclerosis: Precise Diagnosis and Individualized Treatment.2017Chinese medical journal
All its trials on ClinicalTrials.gov, any status4
  1. Explore Neuroprotective Effect of Lipoic Acid in Amyotrophic Lateral SclerosisStatus unknownNCT04518540Lead sponsorN/AStart 2020-09
  2. A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RAG-17 in Subjects With Amyotrophic Lateral Sclerosis (ALS) With Superoxide Dismutase Type 1 (SOD1) Gene MutationRecruitingNCT06556394Study sitePhase 1Start 2024-12
  3. A Phase Ⅰ/Ⅱa Study of SNUG01 in Adult Subjects With ALSNot yet recruitingNCT07169175Study sitePhase 1/Phase 2Start 2025-12
  4. An IIT Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of a Single Intrathecal Injection of SNUG01 in Patients with Amyotrophic Lateral SclerosisNot yet recruitingNCT06645197Study siteEarly phase 1Start 2024-10

Run the PubMed searchClinicalTrials.gov

Other diseases

Fabry disease

法布雷病

Led no English-language PubMed papers on Fabry disease in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution

7 hospitals in Hangzhou for Fabry disease85 hospitals in China for Fabry disease

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Study of Agalsidase Alfa Enyzme Replacement Therapy in Chinese Children and Adults With Fabry Disease
    Phase
    Not given
    Started
    2025-11
    Registry
    NCT07187440

    Age 7 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 18 listed hospitals as study sitesBeijing, Chengdu, Fuzhou, Hangzhou, Harbin, Hefei, Nanjing, Shantou, Shenzhen, Shijiazhuang, Suzhou, Taiyuan, Tianjin, Xi'an

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
All its trials on ClinicalTrials.gov, any status1
  1. A Study of Agalsidase Alfa Enyzme Replacement Therapy in Chinese Children and Adults With Fabry DiseaseRecruitingNCT07187440Study siteStart 2025-11

Run the PubMed searchClinicalTrials.gov

Other diseases

Pompe disease

庞贝病

Led no English-language PubMed papers on Pompe disease in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

2 hospitals in Hangzhou for Pompe disease30 hospitals in China for Pompe disease

No open trial on Pompe disease lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNeurology
Chinese-language papers (not in the count)1
  1. [Multiple disciplinary team for Pompe disease].2023Zhonghua nei ke za zhi

Run the PubMed searchClinicalTrials.gov

Other diseases

Duchenne muscular dystrophy

杜氏肌营养不良

Led 1 of the 213 English-language PubMed papers on Duchenne muscular dystrophy with an author in mainland China, 2021–2025: 0.5%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

7 hospitals in Hangzhou for Duchenne muscular dystrophy116 hospitals in China for Duchenne muscular dystrophy

No open trial on Duchenne muscular dystrophy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Behçet disease

白塞病

Led no English-language PubMed papers on Behçet disease in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

7 hospitals in Hangzhou for Behçet disease149 hospitals in China for Behçet disease

No open trial on Behçet disease lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
All its trials on ClinicalTrials.gov, any status1
  1. A Registry Study Assessing PRO, Dosing Patterns, and Safety of Vunakizumab in Patients With General Rheumatic Diseases.Not yet recruitingNCT06766552Lead sponsorStart 2025-01

Run the PubMed searchClinicalTrials.gov

Other diseases

Alport syndrome

Alport 综合征

Led 1 of the 58 English-language PubMed papers on Alport syndrome with an author in mainland China, 2021–2025: 1.7%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 0020242025: 002025

4 hospitals in Hangzhou for Alport syndrome60 hospitals in China for Alport syndrome

No open trial on Alport syndrome lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersOphthalmology / neuro-ophthalmology

Run the PubMed searchClinicalTrials.gov

Other diseases

IgA nephropathy

IgA 肾病

Led 2 of the 736 English-language PubMed papers on IgA nephropathy with an author in mainland China, 2021–2025: 0.3%.

Papers led
2
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 112025

15 hospitals in Hangzhou for IgA nephropathy346 hospitals in China for IgA nephropathy

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Study of Mezagitamab in Adults With Kidney Condition Called IgA Nephropathy
    Phase
    Phase 3
    Started
    2025-07
    Registry
    NCT06963827

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 20 listed hospitals as study sitesBaotou, Beijing, Changsha, Chengdu, Guangzhou, Hangzhou, Jinan, Nanchang, Nanjing, Nantong, Ningbo, Shanghai, Shenzhen, Wuxi, Xiamen, Zhuhai

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersNephrology

Run the PubMed searchClinicalTrials.gov

Other diseases

Osteogenesis imperfecta

成骨不全症

Led no English-language PubMed papers on osteogenesis imperfecta in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

2 hospitals in Hangzhou for osteogenesis imperfecta59 hospitals in China for osteogenesis imperfecta

No open trial on osteogenesis imperfecta lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Congenital diaphragmatic hernia

先天性膈疝

Led 1 of the 60 English-language PubMed papers on congenital diaphragmatic hernia with an author in mainland China, 2021–2025: 1.7%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

3 hospitals in Hangzhou for congenital diaphragmatic hernia46 hospitals in China for congenital diaphragmatic hernia

No open trial on congenital diaphragmatic hernia lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersRadiology / nuclear medicine

Run the PubMed searchClinicalTrials.gov

Other diseases

Hirschsprung disease

先天性巨结肠

Led 1 of the 161 English-language PubMed papers on Hirschsprung disease with an author in mainland China, 2021–2025: 0.6%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 0020242025: 002025

3 hospitals in Hangzhou for Hirschsprung disease82 hospitals in China for Hirschsprung disease

No open trial on Hirschsprung disease lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNeurology
Papers it led1
  1. Mesenteric Neural Crest Cells Are the Embryological Basis of Skip Segment Hirschsprung's Disease.2021Cellular and molecular gastroenterology and hepatology

Run the PubMed searchClinicalTrials.gov

Other diseases

Hereditary angioedema

遗传性血管性水肿

Led 1 of the 32 English-language PubMed papers on hereditary angioedema with an author in mainland China, 2021–2025: 3.1%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

1 hospital in Hangzhou for hereditary angioedema30 hospitals in China for hereditary angioedema

No open trial on hereditary angioedema lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersRheumatology & immunology

Run the PubMed searchClinicalTrials.gov

Other diseases

Familial adenomatous polyposis

家族性腺瘤性息肉病

Led 4 of the 59 English-language PubMed papers on familial adenomatous polyposis with an author in mainland China, 2021–2025: 6.8%.

Papers led
4
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 2220212022: 0020222023: 2220232024: 0020242025: 002025

4 hospitals in Hangzhou for familial adenomatous polyposis76 hospitals in China for familial adenomatous polyposis

No open trial on familial adenomatous polyposis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersMedical oncology

Run the PubMed searchClinicalTrials.gov

Other diseases

Leber hereditary optic neuropathy

Leber 遗传性视神经病变

Led no English-language PubMed papers on Leber hereditary optic neuropathy in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

5 hospitals in Hangzhou for Leber hereditary optic neuropathy32 hospitals in China for Leber hereditary optic neuropathy

No open trial on Leber hereditary optic neuropathy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Earlier papers (2016–2020)1
  1. Mitochondrial tRNAThr 15891C>G mutation was not associated with Leber's hereditary optic neuropathy in Han Chinese patients.2016Mitochondrial DNA. Part A, DNA mapping, sequencing, and analysis

Run the PubMed searchClinicalTrials.gov

Getting in touch

Name card to show staff or a driver

浙江大学医学院附属第二医院

Second Affiliated Hospital, Zhejiang University

杭州

Large hospitals often have several campuses. Confirm the campus with the hospital before travelling.

Inquiry letter in English and Chinese

Fill in the brackets, then send it through the contact options on the hospital's international office or official website. Nothing typed here leaves this device.

Records hospitals usually ask for

  • A recent summary or letter from the treating doctor
  • Pathology report
  • Scans (CT, MRI, PET) with their reports, and the images if possible
  • Treatments so far, with dates
  • Current medicines

What to do next

Talk with the treating doctorThis page can be shared with the treating doctor to discuss whether this team's work is relevant.
Check the team is still therePapers lag by months and doctors move. Look at the hospital's own pages linked above.
Contact the hospital directlyUse the hospital's own contacts. Hospitals never pay us, and each hospital decides which patients it accepts.

Where these numbers come from

Papers

English-language PubMed papers whose first or last author lists this hospital as their first affiliation, 2021–2025. Definitions

Trials

ClinicalTrials.gov records naming this hospital as lead sponsor or site, as of 8 Nov 2026.

Identifiers and other names

ROR
Second Affiliated Hospital of Zhejiang University; Second Affiliated Hospital of Zhejiang University of Medicine; Second Affiliated Hospital Zhejiang University; Second Affiliated Hospital Zhejiang University College of Medicine; Second Affiliated Hospital of Zhejiang University Medical College; SAHZU

Suggest a correctionDownload the data